BioMark Diagnostics (20B) Stock Statistics & Valuation Metrics
Total Valuation
BioMark Diagnostics has a market cap or net worth of EUR 31.96M. The enterprise value is EUR 58.98M.
- Market Cap
- EUR 31.96M
- Enterprise Value
- EUR 58.98M
Share Statistics
BioMark Diagnostics has 106,483,440 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 106,483,440
- Owned by Insiders
- 53.45%
- Owned by Institutions
- ―
Financial Efficiency
BioMark Diagnostics’s return on equity (ROE) is -4.46 and return on invested capital (ROIC) is -163.31%.
- Return on Equity (ROE)
- -4.46
- Return on Assets (ROA)
- -0.79
- Return on Invested Capital (ROIC)
- -163.31%
- Return on Capital Employed (ROCE)
- -2.45
- Revenue Per Employee
- 6,643
- Profits Per Employee
- -164.13K
- Employee Count
- 9
- Asset Turnover
- 0.03
- Inventory Turnover
- 0.00
Valuation Ratios
The current PE Ratio of BioMark Diagnostics is -34.81. BioMark Diagnostics’s PEG ratio is -1.01.
- PE Ratio
- -34.81
- PS Ratio
- 1800.06
- PB Ratio
- 87.51
- Price to FCF
- -46.95
- Price to Operating Cash Flow
- -47.00
- PEG Ratio
- -1.01
Income Statement
In the last 12 months, BioMark Diagnostics had revenue of 59.79K and earned -1.48M in profits. Earnings per share was -0.01.
- Revenue
- 59.79K
- Gross Profit
- -322.49K
- Operating Income
- -1.87M
- Pretax Income
- -1.60M
- Net Income
- -1.48M
- EBITDA
- -1.49M
- Earnings Per Share (EPS)
- -0.01
Cash Flow
In the last 12 months, operating cash flow was -1.06M and capital expenditures -2,232, giving a free cash flow of -1.07M billion.
- Operating Cash Flow
- -1.06M
- Free Cash Flow
- -1.07M
- Free Cash Flow per Share
- -0.01
Dividends & Yields
BioMark Diagnostics pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -2.13%
- Earnings Yield
- -2.85%
Stock Price Statistics
- Beta
- 0.20
- 52-Week Price Change
- 37.82%
- 50-Day Moving Average
- 0.29
- 200-Day Moving Average
- 0.32
- Relative Strength Index (RSI)
- 34.60
- Average Volume (3m)
- 1,500
Important Dates
BioMark Diagnostics upcoming earnings date is Nov 27, 2026, TBA (Not Confirmed).
- Last Earnings Date
- Aug 28, 2026
- Next Earnings Date
- Nov 27, 2026
- Ex-Dividend Date
- ―
Financial Position
BioMark Diagnostics as a current ratio of 0.99, with Debt / Equity ratio of 218.95%
- Current Ratio
- 0.99
- Quick Ratio
- 0.99
- Debt to Market Cap
- 0.00
- Net Debt to EBITDA
- -0.07
- Interest Coverage Ratio
- -29.59
Taxes
In the past 12 months, BioMark Diagnostics has paid -126.23K in taxes.
- Income Tax
- -126.23K
- Effective Tax Rate
- 0.08
Enterprise Valuation
BioMark Diagnostics EV to EBITDA ratio is -34.37, with an EV/FCF ratio of -47.46.
- EV to Sales
- 1819.53
- EV to EBITDA
- -34.37
- EV to Free Cash Flow
- -47.46
- EV to Operating Cash Flow
- -47.56
Balance Sheet
BioMark Diagnostics has EUR 788.32K in cash and marketable securities with EUR 1.27M in debt, giving a net cash position of -EUR 482.90K billion.
- Cash & Marketable Securities
- EUR 788.32K
- Total Debt
- EUR 1.27M
- Net Cash
- -EUR 482.90K
- Net Cash Per Share
- EUR 0.00
- Tangible Book Value Per Share
- EUR 0.01
Margins
Gross margin is -1273.73%, with operating margin of -6782.46%, and net profit margin of -5127.11%.
- Gross Margin
- -1273.73%
- Operating Margin
- -6782.46%
- Pretax Margin
- -5581.12%
- Net Profit Margin
- -5127.11%
- EBITDA Margin
- -5293.62%
- EBIT Margin
- -6667.35%
Analyst Forecast
The average price target for BioMark Diagnostics is ―, which is 11.43% higher than the current price. The consensus rating is ―
- Price Target
- ―
- Price Target Upside
- ―
- Analyst Consensus
- ―
- Analyst Count
- ―
- Revenue Growth Forecast
- -83.10%
- EPS Growth Forecast
- 28.21%